Trials / Completed
CompletedNCT04085601
A Study to Evaluate the Efficacy and Safety of Pegcetacoplan in Patients With PNH
A Phase 3, Randomized, Multicenter, Open-Label, Controlled Study to Evaluate the Efficacy and Safety of Pegcetacoplan in Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH)
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 53 (actual)
- Sponsor
- Apellis Pharmaceuticals, Inc. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Evaluation of the Efficacy and Safety of Pegcetacoplan in Patients with Paroxysmal Nocturnal Hemoglobinuria .
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | APL-2 | Complement (C3) Inhibitor |
Timeline
- Start date
- 2019-08-27
- Primary completion
- 2021-06-23
- Completion
- 2021-06-23
- First posted
- 2019-09-11
- Last updated
- 2022-10-21
- Results posted
- 2022-10-21
Locations
30 sites across 10 countries: Colombia, Hong Kong, Malaysia, Mexico, Peru, Philippines, Poland, Serbia, Singapore, Thailand
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04085601. Inclusion in this directory is not an endorsement.